Alnylam, Sanofi flag another promising step forward for PhIII hemophilia drug
Alnylam $ALNY and its partners at Sanofi $SNY say their hemophilia drug fitusiran has taken a promising step forward in the clinic, clearing another leg of a Phase II study with continued evidence of safety and efficacy that backs its recent move into a pivotal trial.
Fitusiran was one of the key reasons why Sanofi decided to buy into Alnylam and its RNAi approach with a $700 million equity deal three years ago. And it’s also central now to Alnylam’s case to investors that its Phase III pipeline is growing with promising new meds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
